BIOCORP: A new agreement with Roche France - FV increased to EUR32 | CORPORATE | EUR32 vs. EUR25
BIOCORP - CORPORATE | EUR32 vs. EUR25 (+27%)A new agreement with Roche France - FV increased to EUR32
Second big diabetes player to sign with Biocorp
Mallya the device of choice for insulin pens
EUR100m peak sales for Mallya
Higher chances of reaching peak sales - FV increased to EUR32
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.